{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:11Z","timestamp":1790283551020,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005860","name":"Helsefonden","doi-asserted-by":"publisher","award":["20-B-0003"],"award-info":[{"award-number":["20-B-0003"]}],"id":[{"id":"10.13039\/501100005860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R246-A14574-19-S73"],"award-info":[{"award-number":["R246-A14574-19-S73"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005940","name":"Dansk Kraeftforsknings Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105225","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:06:21Z","timestamp":1771488381000},"page":"105225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"221","author":[{"given":"Christina M.S.","family":"Hassing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Bogh","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove Holst Filtenborg","family":"Tvedskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Lisbet","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S\u00f8egaard","family":"Knoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Thorndahl","family":"Kroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"K\u00fcmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.critrevonc.2026.105225_bib1","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/cncr.32878","article-title":"Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature","volume":"126","author":"An","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/tbj.13288","article-title":"Outcomes in patients with small node-negative invasive breast cancer","volume":"25","author":"Bao","year":"2019","journal-title":"Breast J."},{"key":"10.1016\/j.critrevonc.2026.105225_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ijc.22892","article-title":"Prognostic effect of estrogen receptor status across age in primary breast cancer","volume":"122","author":"Bentzon","year":"2008","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clbc.2023.08.002","article-title":"Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer","volume":"23","author":"Bravo-Solarte","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105225_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-023-07132-6","article-title":"Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer","volume":"203","author":"Carbajal-Ochoa","year":"2023","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105225_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clbc.2015.10.001","article-title":"Analysis of Risk of Recurrence by Subtype in <\/= 1-cm Breast Tumors","volume":"16","author":"Colonna","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib8","unstructured":"Danish Breast Cancer Group, 2024. Systemisk behandling af brystkr\u00e6ft - II [WWW Document]. URL \u3008https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer\/opdelt-paa-dmcg\/brystcancer\/behandling\/dbcg_praoperativ-og-adjuve-syst-bh-af-tidlig-brystkraft_v3.0_admgodk_211024.pdf\u3009 (accessed 10.24.25)."},{"key":"10.1016\/j.critrevonc.2026.105225_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.06.043","article-title":"Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study","volume":"84","author":"de Nonneville","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib10","first-page":"1","article-title":"St. Gallen\/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference","author":"Ditsch","year":"2025","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105225_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-021-06481-4","article-title":"Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer","volume":"192","author":"Fasano","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105225_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-022-06839-2","article-title":"Adjuvant chemotherapy in patients with ER-negative\/HER2-negative, T1abN0 breast cancer: a nationwide study","volume":"198","author":"Hassing","year":"2023","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105225_bib14","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. et. al., editors, 2024. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)., 6.5. ed. Cochrane, 2024. Available from \u3008www.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.critrevonc.2026.105225_bib15","first-page":"4944","article-title":"Favorable prognosis in patients with T1a\/T1bN0 triple-negative breast","volume":"118","author":"Ho","year":"2012","journal-title":"Cancers Treat. Multimodal Ther. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib16","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1245\/s10434-023-13977-4","article-title":"Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer","volume":"30","author":"Huang","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105225_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105225_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/1471-2407-10-557","article-title":"Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less","volume":"10","author":"Kwon","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105225_bib20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105225_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1159\/000533149","article-title":"Retrospective Study of Treatment Patterns and Natural History of Patients with T1a\/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience","volume":"101","author":"Liu","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2026.105225_bib22","first-page":"30","article-title":"Benefit of adjuvant chemotherapy for T1cN0M0 and selected T1bN0M0 triple-negative breast cancer: a nationwide cancer registry-based study","author":"Lo","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105225_bib23","first-page":"46","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 5 behalf of the ESMO Guidelines Committee","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105225_bib24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12885-017-3929-6","article-title":"Outcome of breast cancer screening in Denmark","volume":"17","author":"Lynge","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib25","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105225_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clbc.2025.05.022","article-title":"Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis","volume":"25","author":"Moraes","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib27","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)) Version 5.2025 [WWW Document], 2025. URL \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\u3009 (accessed 10.22.25)."},{"key":"10.1016\/j.critrevonc.2026.105225_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-013-2423-3","article-title":"Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study","volume":"138","author":"Olszewski","year":"2013","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105225_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2022.12.004","article-title":"Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis","volume":"67","author":"Petrelli","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105225_bib30","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, 2024. 2024","article-title":"Chapter 24: Including non-randomized studies on intervention effects [last updated October 2019]","author":"Reeves","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105225_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2018.11.011","article-title":"Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer","volume":"43","author":"Ren","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105225_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12032-022-01829-2","article-title":"Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database","volume":"39","author":"Shum","year":"2022","journal-title":"Med Oncol."},{"key":"10.1016\/j.critrevonc.2026.105225_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2020.04.033","article-title":"Adjuvant chemotherapy in small node-negative triple-negative breast cancer","volume":"135","author":"Steenbruggen","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105225_bib34","unstructured":"The Danish Institute for Quality and Accreditation in Healthcare, 2025. Danish Breast Cancer Group Quality Database - National annual report 2024 [WWW Document]. URL \u3008https:\/\/www.sundk.dk\/media\/l2rp4h4c\/dbcg-a-rsrapport-2024_offentliggjort-version-20250627.pdf\u3009 (accessed 10.14.25)."},{"key":"10.1016\/j.critrevonc.2026.105225_bib35","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","article-title":"Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105225_bib36","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., n.d. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [WWW Document]. URL \u3008https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\u3009 (accessed 12.11.24)."},{"key":"10.1016\/j.critrevonc.2026.105225_bib37","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.21037\/gs-23-189","article-title":"Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis","volume":"12","author":"Wu","year":"2023","journal-title":"Gland Surg."},{"key":"10.1016\/j.critrevonc.2026.105225_bib38","article-title":"Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis","volume":"25","author":"Yang","year":"2020","journal-title":"Cancer Treat. Res Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:37:58Z","timestamp":1778794678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S1040842826001125"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105225","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105225"}}